Base de dados : MEDLINE
Pesquisa : C04.557.450.565.465.249 [Categoria DeCS]
Referências encontradas : 281 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 29 ir para página                         

  1 / 281 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460419
[Au] Autor:Milovancev M; Townsend KL; Gorman E; Bracha S; Curran K; Russell DS
[Ad] Endereço:Department of Clinical Sciences, College of Veterinary Medicine, Oregon State University, Corvallis, Oregon.
[Ti] Título:Shaved margin histopathology and imprint cytology for assessment of excision in canine mast cell tumors and soft tissue sarcomas.
[So] Source:Vet Surg;46(6):879-885, 2017 Aug.
[Is] ISSN:1532-950X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To determine the feasibility and agreement of margin assessment by imprint cytology, shaved margin histopathology, and radial section histopathology in canine cutaneous and subcutaneous mast cell tumors (MCT) and soft tissue sarcomas (STS). STUDY DESIGN: Prospective clinical study. SAMPLE POPULATION: Three hundred and forty margins from 72 excised tumors (52 MCT and 20 STS) in 54 client-owned dogs. METHODS: Imprint cytology samples were acquired by pressing glass slides to the cut surgical margin of the freshly excised surgical specimen. Shaved margin samples were obtained from the patient wound bed using a scalpel immediately prior to closure. Radial section histopathology was performed as part of routine histopathologic processing. All margins were assessed as either positive or negative for presence of tumor cells at the surgical margin. Agreement among methods was calculated using Fleiss Kappa coefficients and an association of method, margin direction, and tumor type with positive margin status was evaluated using a general linear mixed model. RESULTS: Positive margin detection rates differed for MCT (imprint cytology 21%, radial section histopathology 9%, and shaved margin histopathology 3%; P < .0001) but not for STS. Intermethod agreement was poor (Fleiss Kappa = 0.051 and 0.176 for MCT and STS, respectively). Margin direction did not influence margin status for either tumor type. CONCLUSION: Imprint cytology and shaved margin histopathology are feasible, but their results are frequently disparate from routine radial section histopathology. Future studies are needed to evaluate the correlation of each method with local recurrence rates.
[Mh] Termos MeSH primário: Citodiagnóstico/veterinária
Doenças do Cão/cirurgia
Mastocitoma/veterinária
Sarcoma/veterinária
Cirurgia Veterinária/métodos
[Mh] Termos MeSH secundário: Animais
Citodiagnóstico/métodos
Cães
Feminino
Masculino
Mastocitoma/cirurgia
Estudos Prospectivos
Sarcoma/cirurgia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1111/vsu.12668


  2 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28266316
[Au] Autor:Jark PC; Mundin DB; de Carvalho M; Ferioli RB; Anai LA; Marchi FA; Rogatto SR; Laufer-Amorim R; Tinucci-Costa M
[Ad] Endereço:Clinical Veterinary Department, College of Agricultural and Veterinary Sciences, São Paulo State University "Júlio de Mesquita Filho" (UNESP), Jaboticabal, São Paulo, Brazil. Electronic address: paulocjark@hotmail.com.
[Ti] Título:Genomic copy number variation associated with clinical outcome in canine cutaneous mast cell tumors.
[So] Source:Res Vet Sci;111:26-30, 2017 Apr.
[Is] ISSN:1532-2661
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mast cell tumors are the most common malignant cutaneous tumors in dogs. Although there are several prognostic factors involved, the clinical and biological behavior of this type of tumor varies greatly, making the best choice of treatment challenging. Molecular techniques can be used to evaluate a large number of genes involved in the neoplastic process and aid in the selection of candidate genes related to prognostic and predicting factors. Identification of the genes associated with tumor development and progression can be performed through the analysis of numerical and structural changes in DNA isolated from tumor cells by array comparative genomic hybridization (aCGH). The aim of this study was to compare copy number variations (CNVs) in cutaneous mast cell tumors of dogs that survived less than six (ST<6) and >12months (ST>12) from the date of diagnosis. Ten animals were used: four from Group ST>12 and six from Group ST<6. Genomic DNA was extracted, and aCGH was performed using Agilent Canine Genome CGH Microarray 4×180 (ID-252 552 - Agilent, USA). Data analysis was carried out using Nexus program version 5.0 (Biodiscovery, USA). The group ST>12 presented 11±3.3 CNVs, while the ST<6 group presented 85±38.5 CNVs. Regions of loss in PTEN and FAS as well as regions of gains in MAPK3, WNT5B, FGF, FOXM1 and RAD51 were detected in mast cell tumors with shorter survival times, and thus, worst prognoses, allowing for the identification of potential candidate genes for more detailed studies.
[Mh] Termos MeSH primário: Variações do Número de Cópias de DNA
Doenças do Cão/genética
Genômica
Mastocitoma/veterinária
[Mh] Termos MeSH secundário: Animais
Hibridização Genômica Comparativa/métodos
DNA de Neoplasias/genética
Doenças do Cão/metabolismo
Cães
Dosagem de Genes
Mastocitoma/genética
Mastocitoma/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Neoplasm)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170308
[St] Status:MEDLINE


  3 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27889201
[Au] Autor:Giuliano A; Dos Santos Horta R; Constantino-Casas F; Hoather T; Dobson J
[Ad] Endereço:University of Cambridge, Department of Veterinary Medicine, Madingley Road, Cambridge, UK. Electronic address: ag847@cam.ac.uk.
[Ti] Título:Expression of Fibroblast Activating Protein and Correlation with Histological Grade, Mitotic Index and Ki67 Expression in Canine Mast Cell Tumours.
[So] Source:J Comp Pathol;156(1):14-20, 2017 Jan.
[Is] ISSN:1532-3129
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Fibroblast activating protein (FAP) is a membrane serine protease expressed by activated fibroblasts, particularly tumour associated fibroblasts (TAFs). FAP expression has not been reported in canine mast cell tumours (MCTs). The objective of this study was to evaluate the expression of FAP in TAFs and its correlation with histological grade, mitotic index and Ki67 expression in canine MCTs. FAP expression was evaluated by immunohistochemistry (IHC) in 30 canine MCTs. Twenty-eight (90%) of the MCTs expressed FAP in the stroma, 16 cases showed low to intermediate FAP score and 14 cases had a high FAP score. FAP was correlated positively with both Patnaik (P = 0.007) and Kiupel (P = 0.008) grading systems, mitotic index (P = 0.0008) and Ki67 expression (P = 0.009). High stromal FAP expression could be a potential negative prognostic factor in canine MCTs.
[Mh] Termos MeSH primário: Doenças do Cão/patologia
Fibroblastos/patologia
Gelatinases/biossíntese
Sarcoma de Mastócitos/veterinária
Mastocitoma/veterinária
Proteínas de Membrana/biossíntese
Serina Endopeptidases/biossíntese
[Mh] Termos MeSH secundário: Animais
Doenças do Cão/metabolismo
Cães
Imuno-Histoquímica
Antígeno Ki-67/biossíntese
Índice Mitótico
Gradação de Tumores
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ki-67 Antigen); 0 (Membrane Proteins); EC 3.4.21.- (Serine Endopeptidases); EC 3.4.21.- (fibroblast activation protein alpha); EC 3.4.24.- (Gelatinases)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170525
[Lr] Data última revisão:
170525
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161128
[St] Status:MEDLINE


  4 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27716898
[Au] Autor:Frick M; Mouchacca P; Verdeil G; Hamon Y; Billaudeau C; Buferne M; Fallet M; Auphan-Anezin N; Schmitt-Verhulst AM; Boyer C
[Ad] Endereço:Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université UM2, Inserm, U1104, CNRS UMR7280, Marseille, France.
[Ti] Título:Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca signalling and granule mobilization.
[So] Source:Immunology;150(2):199-212, 2017 Feb.
[Is] ISSN:1365-2567
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Cancer-germline genes in both humans and mice have been shown to encode antigens susceptible to targeting by cytotoxic CD8 T effector cells (CTL). We analysed the ability of CTL to kill different tumour cell lines expressing the same cancer-germline gene P1A (Trap1a). We previously demonstrated that CTL expressing a T-cell receptor specific for the P1A peptide associated with H-2L , although able to induce regression of P1A-expressing P815 mastocytoma cells, were much less effective against P1A-expressing melanoma cells. Here, we analysed parameters of the in vitro interaction between P1A-specific CTL and mastocytoma or melanoma cells expressing similar levels of the P1A gene and of surface H-2L . The mastocytoma cells were more sensitive to cytolysis than the melanoma cells in vitro. Analysis by video-microscopy of early events required for target cell killing showed that similar patterns of increase in cytoplasmic Ca concentration ([Ca ]i) were induced by both types of P1A-expressing tumour cells. However, the use of CTL expressing a fluorescent granzyme B (GZMB-Tom) showed a delay in the migration of cytotoxic granules to the tumour interaction site, as well as a partially deficient GZMB-Tom exocytosis in response to the melanoma cells. Among surface molecules possibly affecting tumour-CTL interactions, the mastocytoma cells were found to express intercellular adhesion molecule-1, the ligand for LFA-1, which was not detected on the melanoma cells.
[Mh] Termos MeSH primário: Antígenos de Neoplasias/metabolismo
Exocitose
Mastocitoma/imunologia
Melanoma/imunologia
Fragmentos de Peptídeos/metabolismo
Vesículas Secretórias/metabolismo
Linfócitos T Citotóxicos/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos de Neoplasias/genética
Sinalização do Cálcio
Linhagem Celular Tumoral
Citotoxicidade Imunológica
Antígeno de Histocompatibilidade H-2D/metabolismo
Seres Humanos
Molécula 1 de Adesão Intercelular/metabolismo
Ativação Linfocitária
Antígeno-1 Associado à Função Linfocitária/metabolismo
Camundongos
Especificidade do Receptor de Antígeno de Linfócitos T
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, Neoplasm); 0 (Histocompatibility Antigen H-2D); 0 (Lymphocyte Function-Associated Antigen-1); 0 (Peptide Fragments); 0 (cancer-testis antigen P1A, mouse); 126547-89-5 (Intercellular Adhesion Molecule-1)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170517
[Lr] Data última revisão:
170517
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161008
[St] Status:MEDLINE
[do] DOI:10.1111/imm.12679


  5 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27627984
[Au] Autor:Romanucci M; Massimini M; Ciccarelli A; Malatesta D; Bongiovanni L; Gasbarre A; Della Salda L
[Ad] Endereço:1 Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy.
[Ti] Título:HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors.
[So] Source:Vet Pathol;54(2):222-225, 2017 Mar.
[Is] ISSN:1544-2217
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Literature data indicate heat shock protein (Hsp) 32 and 90 as potential molecular targets in canine neoplastic mast cells (MCs). However, their immunoexpression patterns in canine mast cell tumors (MCTs) have not been investigated. Thus, the aim of this study was to evaluate the immunohistochemical expression of Hsp32 and Hsp90 in 22 canine cutaneous MCTs, in relation to KIT immunolabeling pattern, histological grade, and mitotic count. All cases showed cytoplasmic labeling of Hsp90, variably associated with nuclear and/or membranous labeling. Relationships of Hsp90 or Hsp32 immunolabeling with KIT pattern, mitotic count, and tumor grade were not observed. However, the reduced Hsp32 immunoexpression observed in most grade III/high-grade MCTs suggests a tendency toward a loss of immunosignal in poorly differentiated MCs. The great heterogeneity in extent and distribution of Hsp90 immunoexpression among the different MCT cases may also partially explain the difficulties in predicting the in vivo biologic activity of Hsp90 inhibitors on canine MCTs.
[Mh] Termos MeSH primário: Doenças do Cão/metabolismo
Proteínas de Choque Térmico/metabolismo
Mastocitoma/veterinária
Proteínas Proto-Oncogênicas c-kit/metabolismo
Neoplasias Cutâneas/veterinária
[Mh] Termos MeSH secundário: Animais
Cães
Regulação Neoplásica da Expressão Gênica
Proteínas de Choque Térmico/genética
Mastocitoma/genética
Mastocitoma/metabolismo
Proteínas Proto-Oncogênicas c-kit/genética
Neoplasias Cutâneas/genética
Neoplasias Cutâneas/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Heat-Shock Proteins); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160916
[St] Status:MEDLINE
[do] DOI:10.1177/0300985816669405


  6 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27611333
[Au] Autor:Kim DK; Beaven MA; Kulinski JM; Desai A; Bandara G; Bai Y; Prussin C; Schwartz LB; Komarow H; Metcalfe DD; Olivera A
[Ad] Endereço:Mast Cell Biology Section, Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
[Ti] Título:Regulation of Reactive Oxygen Species and the Antioxidant Protein DJ-1 in Mastocytosis.
[So] Source:PLoS One;11(9):e0162831, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Neoplastic accumulation of mast cells in systemic mastocytosis (SM) associates with activating mutations in the receptor tyrosine kinase KIT. Constitutive activation of tyrosine kinase oncogenes has been linked to imbalances in oxidant/antioxidant mechanisms in other myeloproliferative disorders. However, the impact of KIT mutations on the redox status in SM and the potential therapeutic implications are not well understood. Here, we examined the regulation of reactive oxygen species (ROS) and of the antioxidant protein DJ-1 (PARK-7), which increases with cancer progression and acts to lessen oxidative damage to malignant cells, in relationship with SM severity. ROS levels were increased in both indolent (ISM) and aggressive variants of the disease (ASM). However, while DJ-1 levels were reduced in ISM with lower mast cell burden, they rose in ISM with higher mast cell burden and were significantly elevated in patients with ASM. Studies on mast cell lines revealed that activating KIT mutations induced constant ROS production and consequent DJ-1 oxidation and degradation that could explain the reduced levels of DJ-1 in the ISM population, while IL-6, a cytokine that increases with disease severity, caused a counteracting transcriptional induction of DJ-1 which would protect malignant mast cells from oxidative damage. A mouse model of mastocytosis recapitulated the biphasic changes in DJ-1 and the escalating IL-6, ROS and DJ-1 levels as mast cells accumulate, findings which were reversed with anti-IL-6 receptor blocking antibody. Our findings provide evidence of increased ROS and a biphasic regulation of the antioxidant DJ-1 in variants of SM and implicate IL-6 in DJ-1 induction and expansion of mast cells with KIT mutations. We propose consideration of IL-6 blockade as a potential adjunctive therapy in the treatment of patients with advanced mastocytosis, as it would reduce DJ-1 levels making mutation-positive mast cells vulnerable to oxidative damage.
[Mh] Termos MeSH primário: Antioxidantes/metabolismo
Mastocitose/metabolismo
Proteína Desglicase DJ-1/metabolismo
Espécies Reativas de Oxigênio/metabolismo
[Mh] Termos MeSH secundário: Transferência Adotiva
Adulto
Animais
Linhagem Celular
Espaço Extracelular/metabolismo
Homeostase
Seres Humanos
Mastócitos/metabolismo
Mastocitoma/patologia
Mastocitose/sangue
Camundongos
Meia-Idade
Mutação/genética
Proteína Desglicase DJ-1/sangue
Proteína Desglicase DJ-1/genética
Proteólise
Proteínas Proto-Oncogênicas c-kit/genética
Proteínas Proto-Oncogênicas c-kit/metabolismo
Espécies Reativas de Oxigênio/sangue
Receptores de Interleucina-6/metabolismo
Transcrição Genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Reactive Oxygen Species); 0 (Receptors, Interleukin-6); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit); EC 3.1.2.- (PARK7 protein, human); EC 3.1.2.- (PARK7 protein, mouse); EC 3.1.2.- (Protein Deglycase DJ-1)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170804
[Lr] Data última revisão:
170804
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160910
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0162831


  7 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27429464
[Au] Autor:Devine L; Polzin DJ
[Ad] Endereço:North Carolina State Veterinary Hospital - Internal Medicine, 1060 William Moore Drive, Raleigh, North Carolina 27607, USA (Devine); University of Minnesota - Internal Medicine, St. Paul, Minnesota, 55108, USA (Polzin).
[Ti] Título:Presumed masitinib-induced nephrotic syndrome and azotemia in a dog.
[So] Source:Can Vet J;57(7):752-6, 2016 Jul.
[Is] ISSN:0008-5286
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:Masitinib mesylate is a tyrosine-kinase inhibitor approved for the treatment of nonresectable or recurrent, Grade 2 or 3 mast cell tumors in dogs. This report describes nephrotic syndrome and acute kidney injury attributed to masitinib and illustrates the need for regular monitoring of serum creatinine concentration, urinalysis, and urine protein:creatinine ratio during its use.
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Azotemia/veterinária
Doenças do Cão/induzido quimicamente
Síndrome Nefrótica/veterinária
Proteínas Tirosina Quinases/antagonistas & inibidores
Tiazóis/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Azotemia/induzido quimicamente
Cães
Feminino
Mastocitoma/tratamento farmacológico
Mastocitoma/veterinária
Síndrome Nefrótica/induzido quimicamente
Tiazóis/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Thiazoles); EC 2.7.10.1 (Protein-Tyrosine Kinases); M59NC4E26P (masitinib)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160719
[St] Status:MEDLINE


  8 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27281113
[Au] Autor:Bartholf DeWitt S; Eward WC; Eward CA; Lazarides AL; Whitley MJ; Ferrer JM; Brigman BE; Kirsch DG; Berg J
[Ad] Endereço:Duke University Medical Center, Durham, North Carolina.
[Ti] Título:A Novel Imaging System Distinguishes Neoplastic from Normal Tissue During Resection of Soft Tissue Sarcomas and Mast Cell Tumors in Dogs.
[So] Source:Vet Surg;45(6):715-22, 2016 Aug.
[Is] ISSN:1532-950X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the ability of a novel imaging system designed for intraoperative detection of residual cancer in tumor beds to distinguish neoplastic from normal tissue in dogs undergoing resection of soft tissue sarcoma (STS) and mast cell tumor (MCT). STUDY DESIGN: Non-randomized prospective clinical trial. ANIMALS: 12 dogs with STS and 7 dogs with MCT. METHODS: A fluorescent imaging agent that is activated by proteases in vivo was administered to the dogs 4-6 or 24-26 hours before tumor resection. During surgery, a handheld imaging device was used to measure fluorescence intensity within the cancerous portion of the resected specimen and determine an intensity threshold for subsequent identification of cancer. Selected areas within the resected specimen and tumor bed were then imaged, and biopsies (n=101) were obtained from areas that did or did not have a fluorescence intensity exceeding the threshold. Results of intraoperative fluorescence and histology were compared. RESULTS: The imaging system correctly distinguished cancer from normal tissue in 93/101 biopsies (92%). Using histology as the reference, the sensitivity and specificity of the imaging system for identification of cancer in biopsies were 92% and 92%, respectively. There were 10/19 (53%) dogs which exhibited transient facial erythema soon after injection of the imaging agent which responded to but was not consistently prevented by intravenous diphenhydramine. CONCLUSION: A fluorescence-based imaging system designed for intraoperative use can distinguish canine soft tissue sarcoma (STS) and mast cell tumor (MCT) tissue from normal tissue with a high degree of accuracy. The system has potential to assist surgeons in assessing the adequacy of tumor resections during surgery, potentially reducing the risk of local tumor recurrence. Although responsive to antihistamines, the risk of hypersensitivity needs to be considered in light of the potential benefits of this imaging system in dogs.
[Mh] Termos MeSH primário: Doenças do Cão/diagnóstico por imagem
Mastocitoma/veterinária
Neoplasia Residual
Sarcoma/veterinária
[Mh] Termos MeSH secundário: Animais
Biópsia
Doenças do Cão/cirurgia
Cães
Feminino
Mastocitoma/diagnóstico por imagem
Mastocitoma/cirurgia
Recidiva Local de Neoplasia/prevenção & controle
Recidiva Local de Neoplasia/veterinária
Estudos Prospectivos
Sarcoma/diagnóstico por imagem
Sarcoma/patologia
Sarcoma/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160610
[St] Status:MEDLINE
[do] DOI:10.1111/vsu.12487


  9 / 281 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27146669
[Au] Autor:Smiech A; Slaska B; Surdyka M; Grzybowska-Szatkowska L; Lopuszynski W; Rózanska D
[Ad] Endereço:Department of Pathological Anatomy, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Gleboka 30 St., 20-612, Lublin, Poland. anna.smiech@up.lublin.pl.
[Ti] Título:Identification of additional mitochondrial DNA mutations in canine mast cell tumours.
[So] Source:Acta Vet Scand;58(1):28, 2016 May 04.
[Is] ISSN:1751-0147
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Research has revealed the presence of somatic mutations in mitochondrial DNA (mtDNA) of certain types of tumours. As this has not been studied for canine mast cell tumours, the aim of this study was to identify mutations in the hypervariable region of mtDNA in mast cell tumours in dogs and determine their association with the process of neoplastic transformation. RESULTS: Samples from 17 dogs with histopathologically confirmed mast cell tumours were analysed. The samples consisted of tumour tissues (n = 17), normal tissues (n = 17), and blood (n = 17). Amplicons of the displacement loop (D-loop) were sequenced and the obtained nucleotide sequences were subjected to bioinformatics analyses. Somatic mutations were detected in seven positions of the D-loop nucleotide sequences in 47 % of the dogs, while polymorphisms were identified in 94 % of the dogs. Most of these changes were homoplasmic, while heteroplasmy was detected in two individuals. Six new haplotypes were established as being characteristic for canine mast cell tumours. There was no association between the presence of the mutations and sex, haplotype, or malignancy grade assessed in 3 and 2-grade scales. CONCLUSIONS: Differences in the frequency of somatic mutations imply their direct association with the neoplastic transformation. However, their functional consequences and clinical significance are not clear. The mutations may be used for diagnosis and prognosis of canine mast cell tumours in the future.
[Mh] Termos MeSH primário: DNA Mitocondrial/genética
Doenças do Cão/genética
Mastócitos/patologia
Mastocitoma/veterinária
Mutação/genética
[Mh] Termos MeSH secundário: Animais
Transformação Celular Neoplásica/genética
Cães
Feminino
Haplótipos
Masculino
Mastocitoma/genética
Polimorfismo Genético
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Mitochondrial)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161231
[Lr] Data última revisão:
161231
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160506
[St] Status:MEDLINE
[do] DOI:10.1186/s13028-016-0210-y


  10 / 281 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27107075
[Au] Autor:Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T
[Ad] Endereço:Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yoshida, Yamaguchi, Japan.
[Ti] Título:Programmed Cell Death Ligand 1 Expression in Canine Cancer.
[So] Source:In Vivo;30(3):195-204, 2016 May-Jun.
[Is] ISSN:1791-7549
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antibody therapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) is a promising therapy in human cancer, but only limited information on PD-L1 expression in canine tumors is available. MATERIALS AND METHODS: PD-L1 expression was examined in 31 canine tumor cell lines of various origins by flow cytometry and western blotting, and in canine tumor and normal tissue specimens by immunohistochemistry. RESULTS: PD-L1 was only expressed on the cell surface of a small number of cell lines but was found expressed within the cells of almost all cell lines. Immunohistochemistry revealed that PD-L1 is frequently expressed in malignant melanoma, mammary gland tumor, mast cell tumor and lymphoma, but less frequently in soft-tissue sarcoma and hemangiosarcoma. PD-L1 was also expressed in some of the cells of normal canine tissue specimens. CONCLUSION: Canine tumors with PD-L1 expression that were identified in this study are potential candidates for antiPD-1 and antiPD-L1 therapy.
[Mh] Termos MeSH primário: Antígeno B7-H1/biossíntese
Doenças do Cão/metabolismo
Neoplasias/veterinária
Receptor de Morte Celular Programada 1/biossíntese
[Mh] Termos MeSH secundário: Animais
Western Blotting
Linhagem Celular Tumoral
Doenças do Cão/patologia
Cães
Citometria de Fluxo
Células HEK293
Seres Humanos
Imuno-Histoquímica
Linfoma/metabolismo
Linfoma/patologia
Linfoma/veterinária
Neoplasias Mamárias Animais/metabolismo
Neoplasias Mamárias Animais/patologia
Mastocitoma/metabolismo
Mastocitoma/patologia
Mastocitoma/veterinária
Melanoma/metabolismo
Melanoma/patologia
Melanoma/veterinária
Neoplasias/metabolismo
Neoplasias/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (B7-H1 Antigen); 0 (Programmed Cell Death 1 Receptor)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160424
[St] Status:MEDLINE



página 1 de 29 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde